<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00359021</url>
  </required_header>
  <id_info>
    <org_study_id>CR002740</org_study_id>
    <secondary_id>TMC125-C217</secondary_id>
    <secondary_id>TMC125-C206</secondary_id>
    <secondary_id>TMC125-C216</secondary_id>
    <nct_id>NCT00359021</nct_id>
  </id_info>
  <brief_title>An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).</brief_title>
  <official_title>An Open-label Trial With TMC125 as Part of an ART Including TMC114/Rtv and an Investigator-selected OBR in HIV-1 Infected Subjects Who Participated in a DUET Phase III Trial (TMC125-C206 or TMC125-C216).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tibotec Pharmaceuticals, Ireland</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tibotec Pharmaceuticals, Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the long-term safety and tolerability of TMC125 200
      mg twice daily as part of an antiretroviral therapy including TMC114/rtv and an investigator
      selected optimized background in HIV-1 infected patients who have participated in a DUET
      trial (TMC125-C206 or TMC125 C216) and have met the definition of virologic failure at Week
      24 or later in these trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III open-label, roll-over trial to evaluate the long term tolerability,
      safety, antiviral and immunological effect of TMC125 as part of an individually optimized
      antiretroviral therapy including TMC114/rtv in HIV-1 infected patients who participated in
      one of the DUET (TMC125-C206 or TMC125-C216) trials. Also the change in HIV-1 resistance over
      time will be evaluated. This trial offers patients meeting the definition of virologic
      failure at Week 24 or beyond the option to roll-over to an open-label trial where they will
      receive TMC125 and TMC114/rtv. Three hundred patients are estimated to enroll into this
      trial. The withdrawal visit of the DUET trial will be the first visit of this trial. From
      this visit onward, all patients will receive 200 mg twice daily TMC125 and 600/100 mg twice
      daily TMC114/rtv until both TMC114 and TMC125 are commercially available or the therapy is no
      longer of clinical benefit to the patient. Patients will receive an antiretroviral therapy
      consisting of TMC125 as the only non-nucleoside reverse transcriptase inhibitor (NNRTI),
      TMC114/rtv as the only protease inhibitor (PI) and an optimized background, which will be
      selected by the investigator according to the local standard of care, the patient's
      experience with previous therapies and most recent resistance testing. The most recent HIV-1
      genotype-analysis system report results from the DUET trial will be made available. TMC125
      will be dosed at 200 mg twice daily, administered orally as 2 tablets twice daily with
      food.TMC114/rtv will be dosed at 600/100 mg twice daily, administered orally as 2 tablets
      TMC114 and 1 capsule ritonavir twice daily with food.The optimized background will comprise
      of at least 1 approved ARV drug: 1 or more NRTI(s), with or without ENF. Administration will
      continue until both TMC114 and TMC125 are commercially available or therapy is no longer of
      clinical benefit to the patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants Experiencing Adverse Events</measure>
    <time_frame>1 week to 180 weeks, with a median of 62 weeks</time_frame>
    <description>The table below provides the number of participants who experienced Serious Adverse Events (SAEs) and Other Adverse Events (except SAEs) that started or worsened in severity during the overall TMC125-C217 treatment period. The duration of treatment ranged per patient from 1 week to 180 weeks, with a median of 62 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants With Virologic Outcomes Over Time</measure>
    <time_frame>Weeks 24, 48, and 96</time_frame>
    <description>The table below shows the percentage of participants with virologic suppression (&lt; 50 copies/mL), the percentage of participants who were virologic failures (VF) (&gt;50 copies/mL, discontinued prior to time X for reasons of VF or for other reasons, except for VF or adverse event, with a last viral load &gt;50 copies/mL), and the percentage of participants with no viral load (VL) data available over time (ie, at Weeks 24, 48, and 96).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Viral Load Versus Baseline (ie, Mean Change in log10 Plasma Viral Load From Baseline Over Time)</measure>
    <time_frame>Baseline, Week 24, Week 48, and Week 96</time_frame>
    <description>In the table below, the total number of participants analyzed in the Duet Placebo and Duet TMC125 groups, respectively at each time point were: Baseline (256;247 participants), Week 24 (251;240 participants), Week 48 (235;192 participants), and Week 96 (123;69 participants).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">503</enrollment>
  <condition>HIV-1</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC125 200 mg twice daily until commercially available</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC125</intervention_name>
    <description>200 mg twice daily until commercially available</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient was previously randomized in a DUET (TMC125-C206 or TMC125-C216) trial and
             completed at least 24 weeks of treatment

          -  Patient was virologically failing in a DUET trial.

        Exclusion Criteria:

          -  Use of disallowed concomitant therapy

          -  Any grade 4 toxicity according to the Division of AIDS (DAIDS) grading table

          -  Patients who had to be withdrawn from the DUET (TMC125-C206 or TMC125-C216) trials
             because of any of the mandatory withdrawal criteria of that trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tibotec Pharmaceuticals Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Tibotec Pharmaceutical Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Laudersale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>N Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safety Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florencio Varela</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neuquen</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darlinghurst</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providencia</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux N/A</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille Cedex 09</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 10</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 15</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris, 75</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif N/A</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad De Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mex Ctity</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona N/A</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2006</study_first_submitted>
  <study_first_submitted_qc>July 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2006</study_first_posted>
  <results_first_submitted>January 29, 2013</results_first_submitted>
  <results_first_submitted_qc>January 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 7, 2013</results_first_posted>
  <last_update_submitted>May 6, 2014</last_update_submitted>
  <last_update_submitted_qc>May 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>treatment experienced</keyword>
  <keyword>virologic failure</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etravirine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants with human immunodeficiency virus – type 1 (HIV-1) infection were enrolled in this study from DUET Study TMC125-C206 or TMC125-C216 and met the definition of virologic failure at Week 24 or later in these studies, or who completed one of the DUET studies after 96 weeks of treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DUET PLACEBO</title>
          <description>Participants who received Placebo in a previous DUET study and received open-label treatment with 200 mg twice daily etravirine, also known as TMC125 (ETR) and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-naïve participants.</description>
        </group>
        <group group_id="P2">
          <title>DUET TMC125</title>
          <description>Participants who received etravirine, also known as TMC125 (ETR) in a previous DUET study and received open-label treatment with 200 mg twice daily ETR and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-experienced participants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
                <participants group_id="P2" count="247"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Non-Compliant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Ineligible To Continue The Trial</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Reached A Virologic Endpoint</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DUET PLACEBO</title>
          <description>Participants who received Placebo in a previous DUET study and received open-label treatment with 200 mg twice daily etravirine, also known as TMC125 (ETR) and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-naïve participants.</description>
        </group>
        <group group_id="B2">
          <title>DUET TMC125</title>
          <description>Participants who received etravirine, also known as TMC125 (ETR) in a previous DUET study and received open-label treatment with 200 mg twice daily ETR and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-experienced participants.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="256"/>
            <count group_id="B2" value="247"/>
            <count group_id="B3" value="503"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.9" spread="8.28"/>
                    <measurement group_id="B2" value="46.6" spread="7.01"/>
                    <measurement group_id="B3" value="46.7" spread="7.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants Experiencing Adverse Events</title>
        <description>The table below provides the number of participants who experienced Serious Adverse Events (SAEs) and Other Adverse Events (except SAEs) that started or worsened in severity during the overall TMC125-C217 treatment period. The duration of treatment ranged per patient from 1 week to 180 weeks, with a median of 62 weeks.</description>
        <time_frame>1 week to 180 weeks, with a median of 62 weeks</time_frame>
        <population>The safety analysis was carried out on the ITT population, which included all participants who received at least one dose of investigational medication.</population>
        <group_list>
          <group group_id="O1">
            <title>DUET PLACEBO</title>
            <description>Participants who received Placebo in a previous DUET study received open-label treatment with 200 mg twice daily etravirine, also known as TMC125 (ETR) and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-naïve participants.</description>
          </group>
          <group group_id="O2">
            <title>DUET TMC125</title>
            <description>Participants who received etravirine, also known as TMC125 (ETR) in a previous DUET study and received open-label treatment with 200 mg twice daily ETR and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-experienced participants.</description>
          </group>
          <group group_id="O3">
            <title>All Participants</title>
            <description>DUET Placebo + DUET TMC125</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Experiencing Adverse Events</title>
          <description>The table below provides the number of participants who experienced Serious Adverse Events (SAEs) and Other Adverse Events (except SAEs) that started or worsened in severity during the overall TMC125-C217 treatment period. The duration of treatment ranged per patient from 1 week to 180 weeks, with a median of 62 weeks.</description>
          <population>The safety analysis was carried out on the ITT population, which included all participants who received at least one dose of investigational medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="503"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events (SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Adverse Events (AEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="137"/>
                    <measurement group_id="O3" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants With Virologic Outcomes Over Time</title>
        <description>The table below shows the percentage of participants with virologic suppression (&lt; 50 copies/mL), the percentage of participants who were virologic failures (VF) (&gt;50 copies/mL, discontinued prior to time X for reasons of VF or for other reasons, except for VF or adverse event, with a last viral load &gt;50 copies/mL), and the percentage of participants with no viral load (VL) data available over time (ie, at Weeks 24, 48, and 96).</description>
        <time_frame>Weeks 24, 48, and 96</time_frame>
        <population>The intent-to-treat (ITT) population was used as the primary analysis population for the efficacy analysis and included all participants who took at least one dose of etravirine (ETR) (also known as TMC125) in the TMC125-C217 study.</population>
        <group_list>
          <group group_id="O1">
            <title>DUET PLACEBO</title>
            <description>Participants who received Placebo in a previous DUET study received open-label treatment with 200 mg twice daily etravirine, also known as TMC125 (ETR) and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-naïve participants.</description>
          </group>
          <group group_id="O2">
            <title>DUET TMC125</title>
            <description>Participants who received etravirine, also known as TMC125 (ETR) in a previous DUET study and received open-label treatment with 200 mg twice daily ETR and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-experienced participants.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants With Virologic Outcomes Over Time</title>
          <description>The table below shows the percentage of participants with virologic suppression (&lt; 50 copies/mL), the percentage of participants who were virologic failures (VF) (&gt;50 copies/mL, discontinued prior to time X for reasons of VF or for other reasons, except for VF or adverse event, with a last viral load &gt;50 copies/mL), and the percentage of participants with no viral load (VL) data available over time (ie, at Weeks 24, 48, and 96).</description>
          <population>The intent-to-treat (ITT) population was used as the primary analysis population for the efficacy analysis and included all participants who took at least one dose of etravirine (ETR) (also known as TMC125) in the TMC125-C217 study.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 - Virologic Response (&lt;50 cop/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0"/>
                    <measurement group_id="O2" value="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - Virologic Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9"/>
                    <measurement group_id="O2" value="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - No VL Data available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 - Virologic Response (&lt;50 cop/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2"/>
                    <measurement group_id="O2" value="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 - Virologic Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4"/>
                    <measurement group_id="O2" value="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 - No VL Data available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 -Virologic Response (&lt;50 cop/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 - Virologic Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0"/>
                    <measurement group_id="O2" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 - No VL Data available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5"/>
                    <measurement group_id="O2" value="68.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Viral Load Versus Baseline (ie, Mean Change in log10 Plasma Viral Load From Baseline Over Time)</title>
        <description>In the table below, the total number of participants analyzed in the Duet Placebo and Duet TMC125 groups, respectively at each time point were: Baseline (256;247 participants), Week 24 (251;240 participants), Week 48 (235;192 participants), and Week 96 (123;69 participants).</description>
        <time_frame>Baseline, Week 24, Week 48, and Week 96</time_frame>
        <population>The intent-to-treat (ITT) population was used as the primary analysis population for the efficacy analysis and included all participants who took at least one dose of etravirine (ETR) (also known as TMC125) in the TMC125-C217 study.</population>
        <group_list>
          <group group_id="O1">
            <title>DUET PLACEBO</title>
            <description>Participants who received Placebo in a previous DUET study received open-label treatment with 200 mg twice daily etravirine, also known as TMC125 (ETR) and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-naïve participants.</description>
          </group>
          <group group_id="O2">
            <title>DUET TMC125</title>
            <description>Participants who received etravirine, also known as TMC125 (ETR) in a previous DUET study and received open-label treatment with 200 mg twice daily ETR and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-experienced participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Viral Load Versus Baseline (ie, Mean Change in log10 Plasma Viral Load From Baseline Over Time)</title>
          <description>In the table below, the total number of participants analyzed in the Duet Placebo and Duet TMC125 groups, respectively at each time point were: Baseline (256;247 participants), Week 24 (251;240 participants), Week 48 (235;192 participants), and Week 96 (123;69 participants).</description>
          <population>The intent-to-treat (ITT) population was used as the primary analysis population for the efficacy analysis and included all participants who took at least one dose of etravirine (ETR) (also known as TMC125) in the TMC125-C217 study.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-0.93" upper_limit="-0.63"/>
                    <measurement group_id="O2" value="0" lower_limit="-0.11" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-0.86" upper_limit="-0.54"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.16" upper_limit="-0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-0.66" upper_limit="-0.30"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.38" upper_limit="-0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>07-Jun-2006 to 24-Jan-2012.</time_frame>
      <desc>All &quot;Serious Adverse Events (SAEs)&quot; emerging during the TMC125-C217 treatment period are reported below; &quot;Other Adverse Events (not including SAEs)&quot; provided below occurred in at least 0.5% of participants. The duration of the TMC125 treatment period ranged per patient from 1 week to 180 weeks, with a median of 62 weeks.</desc>
      <group_list>
        <group group_id="E1">
          <title>DUET PLACEBO</title>
          <description>Participants who received Placebo in a previous DUET study and received open-label treatment with 200 mg twice daily etravirine, also known as TMC125 (ETR) and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-naïve participants.</description>
        </group>
        <group group_id="E2">
          <title>DUET TMC125</title>
          <description>Participants who received etravirine, also known as TMC125 (ETR) in a previous DUET study and received open-label treatment with 200 mg twice daily ETR and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-experienced participants.</description>
        </group>
        <group group_id="E3">
          <title>All Participants</title>
          <description>Participants who received placebo or TMC125 in a previous DUET study (DUET Placebo + DUET TMC125).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="88" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Haemorrhagic diathesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Rectal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Cryptococcosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus chorioretinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus myelomeningoradiculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Hepatitis c</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Histoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Histoplasmosis disseminated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Keratitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Pyomyositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Strongyloidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Tuberculosis of central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Female reproductive tract carcinoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Generalised anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Mood disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Abdominoplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Breast cosmetic surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Liposuction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="297" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="503"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="503"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees that before he/she publishes any results of this trial, he/she shall provide the sponsor with at least 45 days for full review of the pre-publication manuscript prior to submission of the manuscript to the publisher.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>SENIOR DIRECTOR R&amp;D</name_or_title>
      <organization>Tibotec</organization>
      <phone>1 609 730-7548</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

